

Stanford



Neel K. Gupta

Clinical Associate Professor, Medicine - Oncology

CLINICAL OFFICE (PRIMARY)

- **Lymphoma Clinic**

875 Blake Wilbur Dr Clinic C

Stanford, CA 94305

Tel (650) 498-6000 Fax (650) 725-9113

Bio

BIO

Dr. Gupta specializes in the treatment of patients with lymphoma in general, and has particular clinical and research interests in patients with primary central nervous system and immunodeficiency-related lymphomas.

CLINICAL FOCUS

- Cancer > Lymphoma
- Primary Central Nervous System Lymphomas
- Post-transplant Lymphoproliferative Disorders
- AIDS-Related Lymphomas
- Medical Oncology

ACADEMIC APPOINTMENTS

- Clinical Associate Professor, Medicine - Oncology

HONORS AND AWARDS

- Saul Rosenberg Faculty Teaching Award, Division of Oncology, Department of Medicine (2020)
- Saul Rosenberg Faculty Teaching Award, Division of Oncology, Department of Medicine (2018)

PROFESSIONAL EDUCATION

- Board Certification: Medical Oncology, American Board of Internal Medicine (2024)
- Fellowship: UCSF Hematology and Medical Oncology Fellowship (2013) CA
- Residency: University of Washington Medical Center Dept of Medicine (2010) WA
- Medical Education: University of California Davis School of Medicine (2006) CA
- Fellowship: Memorial Sloan-Kettering Cancer Center (2009) NY
- Board Certification: Hematology, American Board of Internal Medicine (2014)

LINKS

- Get a Second Opinion: <https://stanfordhealthcare.org/second-opinion/overview.html>

Research & Scholarship

CURRENT RESEARCH AND SCHOLARLY INTERESTS

I have specific interest in the pathobiology and management of individuals with AIDS-related and primary central nervous system lymphomas.

CLINICAL TRIALS

- A Phase 1b/2 Trial of Hu5F9-G4 in Combination with Rituximab or Rituximab + Chemotherapy in Patients, Not Recruiting
- Phase 1b/2 IPI-145 +/- Rituximab or Obinutuzumab in Previously Untreated CD20+ Follicular Lymphoma, Not Recruiting
- Phase 2 of MK-3475 (Pembrolizumab) in Relapsed or Refractory Classical Hodgkin Lymphoma (cHL), Not Recruiting
- Phase I REGN1979 in CD20+ B-Cell Malignancies Previously Treated w/ CD20-Directed Antibody Therapy, Not Recruiting
- Phase I/II BTK Inhibitor Ibrutinib in Combo w/ MEDI4736 in Relapsed or Refractory Lymphomas, Not Recruiting
- Phase I/II CHOEP Chemo + Lenalidomide as Front Line Tx in Stage II/III & IV Peripheral T-Cell NHL, Not Recruiting
- Phase Ib RO6870810 & Venetoclax +/- Rituximab, in Relapsed/Refractory DLBCL &/or Hi-Grade BCL w/ MYC, Not Recruiting
- Phase II Lisocabtagene Maraleucel (JCAR017) in 2nd-Line Therapy in Adult Aggressive B-cell NHL, Not Recruiting
- Phase II Nivolumab & Brentuximab Vedotin in Untreated HD Over age 60 or Unable to Receive ABVD Chemo, Not Recruiting
- Phase II Tipifarnib in Relapsed or Refractory Peripheral T-Cell Lymphoma, Not Recruiting
- Phase II Tirabrutinib in Primary Central Nervous System Lymphoma (PCNSL), Not Recruiting
- Phase III Axicabtagene Ciloleucel vs SoC Therapy in Relapsed/Refractory Diffuse Large BCell Lymphoma, Not Recruiting
- Phase III Blinatumomab +/- ChemoTx in NewDx Standard Risk /Down Syndrome B-ALL & Tx Localized BB-LLy, Not Recruiting
- Pilot Brentuximab Vedotin + AVD Chemotherapy in Newly Diagnosed Early Stage Risk Hodgkin Lymphoma, Not Recruiting

Publications

PUBLICATIONS

- **Long-term survival in AIDS-related primary central nervous system lymphoma.** *Neuro-oncology*
Gupta, N. K., Nolan, A. n., Omuro, A. n., Reid, E. G., Wang, C. C., Mannis, G. n., Jaglal, M. n., Chavez, J. C., Rubinstein, P. G., Griffin, A. n., Abrams, D. I., Hwang, J. n., Kaplan, et al
2016
- **Lisocabtagene Maraleucel as Second-Line Therapy for R/R Large B-Cell Lymphoma in Patients Not Intended for Hematopoietic Stem Cell Transplant: Final Analysis of the Phase 2 PILOT Study**
Sehgal, A. R., Hoda, D., Riedell, P. A., Ghosh, N., Hamadani, M., Hildebrandt, G., Godwin, J. E., Reagan, P. M., Wagner-Johnston, N., Essell, J., Nath, R., Solomon, S. R., Champion, et al
AMER SOC HEMATOLOGY.2023
- **Implications of Contact Days in the Treatment of Relapsed Refractory Diffuse Large B-Cell Lymphoma.** *The oncologist*
Bojanani, L., Gupta, N., Khaki, A. R.
2023
- **Lisocabtagene maraleucel as second-line therapy in adults with relapsed or refractory large B-cell lymphoma who were not intended for haematopoietic stem cell transplantation (PILOT): an open-label, phase 2 study.** *The Lancet. Oncology*
Sehgal, A., Hoda, D., Riedell, P. A., Ghosh, N., Hamadani, M., Hildebrandt, G. C., Godwin, J. E., Reagan, P. M., Wagner-Johnston, N., Essell, J., Nath, R., Solomon, S. R., Champion, et al
2022
- **Lisocabtagene maraleucel (liso-cel) as second-line (2L) therapy for R/R large B-cell lymphoma (LBCL) in patients (pt) not intended for hematopoietic stem cell transplantation (HSCT): Primary analysis from the phase 2 PILOT study.**

- Sehgal, A., Hoda, D., Riedell, P. A., Ghosh, N., Hamadani, M., Hildebrandt, G., Godwin, J. E., Reagan, P., Wagner-Johnston, N. D., Essell, J., Nath, R., Solomon, S. R., Champion, et al
LIPPINCOTT WILLIAMS & WILKINS.2022
- **CD20-Targeted Therapy Ablates De Novo Antibody Response to Vaccination but Spares Pre-Established Immunity.** *Blood cancer discovery*
Shree, T., Shankar, V., Lohmeyer, J. J., Czerwinski, D. K., Schroers-Martin, J. G., Rodriguez, G. M., Beygi, S., Kanegai, A. M., Corbelli, K. S., Gabriel, E., Kurtz, D. M., Khodadoust, M. S., Gupta, et al
2022
 - **Time Since Last Anti-CD20 Treatment Is a Major Determinant of Sars-Cov-2 Vaccine Response in a Large Cohort of Patients with B-Cell Lymphoma**
Shree, T., Shankar, V., Czerwinski, D. K., Rodriguez, G., Beygi, S., Schroers-Martin, J. G., Advani, R., Maeda, L. S., Gupta, N. K., Khodadoust, M. S., Kurtz, D. M., Corbelli, K. S., Gabriel, et al
AMER SOC HEMATOLOGY.2021
 - **Stage I-II diffuse large B-cell lymphoma treated with rituximab and chemotherapy with or without radiotherapy.** *Leukemia & lymphoma*
Binkley, M. S., Hiniker, S. M., Younes, S., Yoo, C., Wignarajah, A., Jin, M., Guo, H. H., Gupta, N. K., Natkunam, Y., Advani, R. H., Hoppe, R. T.
2021: 1–15
 - **Autologous tumor cell vaccine induces antitumor T cell immune responses in patients with mantle cell lymphoma: A phase I/II trial.** *The Journal of experimental medicine*
Frank, M. J., Khodadoust, M. S., Czerwinski, D. K., Haabeth, O. A., Chu, M. P., Miklos, D. B., Advani, R. H., Alizadeh, A. A., Gupta, N. K., Maeda, L. S., Reddy, S. A., Laport, G. G., Meyer, et al
2020; 217 (9)
 - **Role of FNA with core biopsy or cell block in patients with nodular lymphocyte-predominant Hodgkin lymphoma.** *Cancer cytopathology*
Gupta, S. n., Long, S. R., Natkunam, Y. n., Kong, C. S., Gupta, N. K., Gratzinger, D. n.
2020
 - **Prognostic Value of Circulating Tumor DNA in Diffuse Large B-Cell Lymphoma Reply** *JOURNAL OF CLINICAL ONCOLOGY*
Kurtz, D. M., Scherer, F., Jin, M. C., Soo, J., Craig, A. F. M., Esfahani, M. S., Chabon, J. J., Stehr, H., Liu, C., Tibshirani, R., Maeda, L. S., Gupta, N. K., Khodadoust, et al
2019; 37 (9): 755+
 - **Reply to J. Wang et al.** *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*
Kurtz, D. M., Scherer, F., Jin, M. C., Soo, J., Craig, A. F., Esfahani, M. S., Chabon, J. J., Stehr, H., Liu, C. L., Tibshirani, R., Maeda, L. S., Gupta, N. K., Khodadoust, et al
2019: JCO1801907
 - **AIDS-Related Kaposi Sarcoma, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology.** *Journal of the National Comprehensive Cancer Network : JNCCN*
Reid, E., Suneja, G., Ambinder, R. F., Ard, K., Baiocchi, R., Barta, S. K., Carchman, E., Cohen, A., Crysler, O. V., Gupta, N., Gustafson, C., Hall, A., Johung, et al
2019; 17 (2): 171–89
 - **AIDS-Related Kaposi Sarcoma, Version 2.2019** *JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK*
Reid, E., Suneja, G., Ambinder, R. F., Ard, K., Baiocchi, R., Barta, S. K., Carchman, E., Cohen, A., Crysler, O. V., Gupta, N., Gustafson, C., Hall, A., Johung, et al
2019; 17 (2): 171–89
 - **Circulating Tumor DNA Measurements As Early Outcome Predictors in Diffuse Large B-Cell Lymphoma** *JOURNAL OF CLINICAL ONCOLOGY*
Kurtz, D. M., Scherer, F., Jin, M. C., Soo, J., Craig, A. F. M., Esfahani, M., Chabon, J. J., Stehr, H., Liu, C., Tibshirani, R., Maeda, L. S., Gupta, N. K., Khodadoust, et al
2018; 36 (28): 2845+
 - **Circulating tumor DNA (ctDNA) in B-cell lymphoma**
Scherer, F., Kurtz, D. M., Newman, A. M., Stehr, H., Craig, A. F. M., Esfahani, M. S., Lovejoy, A. F., Chabon, J. J., Klass, D. M., Green, M. R., Liu, C. L., Zhou, L., Glover, et al
WILEY.2018: 16–17

- **Circulating Tumor DNA Measurements As Early Outcome Predictors in Diffuse Large B-Cell Lymphoma.** *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*
Kurtz, D. M., Scherer, F., Jin, M. C., Soo, J., Craig, A. F., Esfahani, M. S., Chabon, J. J., Stehr, H., Liu, C. L., Tibshirani, R., Maeda, L. S., Gupta, N. K., Khodadoust, et al
2018: JCO2018785246
- **Cancer in People Living With HIV, Version 1.2018 Clinical Practice Guidelines in Oncology** *JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK*
Reid, E., Suneja, G., Ambinder, R. F., Ard, K., Baiocchi, R., Barta, S. K., Carchman, E., Cohen, A., Gupta, N., Johung, K. L., Klopp, A., LaCasce, A. S., Lin, et al
2018; 16 (8): 986–1017
- **Development and Validation of Biopsy-Free Genotyping for Molecular Subtyping of Diffuse Large B-Cell Lymphoma** *58th Annual Meeting and Exposition of the American-Society-of-Hematology*
Scherer, F., Kurtz, D. M., Newman, A. M., Esfahani, M. S., Craig, A., Stehr, H., Lovejoy, A. F., Chabon, J. J., Liu, C. L., Zhou, L., Glover, C., Visser, B. C., Poultsides, et al
AMER SOC HEMATOLOGY.2016
- **Noninvasive Detection of BCL2, BCL6, and MYC Translocations in Diffuse Large B-Cell Lymphoma**
Kurtz, D. M., Scherer, F., Newman, A. M., Craig, A., Jin, M., Stehr, H., Chabon, J. J., Esfahani, M., Liu, C., Zhou, L., Glover, C., Visser, B. C., Poultsides, et al
AMER SOC HEMATOLOGY.2016
- **Absence of Evidence Implicating Hematopoietic Stem Cells As Common Progenitors for DLBCL Mutations**
Jan, M., Scherer, F., Kurtz, D. M., Newman, A. M., Stehr, H., Liu, C., Zhou, L., Glover, C., Advani, R. H., Maeda, L. S., Gupta, N. K., Levy, R., Kunder, et al
AMER SOC HEMATOLOGY.2016
- **Distinct biological subtypes and patterns of genome evolution in lymphoma revealed by circulating tumor DNA** *SCIENCE TRANSLATIONAL MEDICINE*
Scherer, F., Kurtz, D. M., Newman, A. M., Stehr, H., Craig, A. F., Esfahani, M. S., Lovejoy, A. F., Chabon, J. J., Klass, D. M., Liu, C. L., Zhou, L., Glover, C., Visser, et al
2016; 8 (364)
- **Noninvasive molecular subtyping and risk stratification of DLBCL.**
Scherer, F., Kurtz, D., Newman, A. M., Stehr, H., Craig, A. F. M., Esfahani, M. S., Lovejoy, A. F., Chabon, J. J., Klass, D. M., Liu, C., Zhou, L., Glover, C., Advani, et al
AMER SOC CLINICAL ONCOLOGY.2016
- **The Transfusion Tether: Bridging the Gap Between End-Stage Hematologic Malignancies and Optimal End-of-Life Care.** *American journal of hematology*
Mannis, G. N., McNey, L. M., Gupta, N. K., Gross, D. M.
2016
- **Plasmablastic lymphoma is treatable in the HAART era. A 10 year retrospective by the AIDS Malignancy Consortium** *LEUKEMIA & LYMPHOMA*
Noy, A., Lensing, S. Y., Moore, P. C., Gupta, N., Aboulafia, D., Ambinder, R., Baiocchi, R., Dezube, B. J., Henry, D., Kaplan, L., Levine, A. M., Mitsuyasu, R., Ratner, et al
2016; 57 (7): 1731–34
- **Phase I/II Clinical Trial of CpG-Activated Whole Cell Vaccine in Mantle Cell Lymphoma (MCL): Results in Safety and Efficacy from Planned Interim Analysis**
Chu, M. P., Brody, J., Kohrt, H. E., Frank, M. J., Khodadoust, M., Reddy, S., Advani, R. H., Gupta, N. K., Laport, G., Maeda, L. S., Meyer, E., Miklos, D. B., Negrin, et al
AMER SOC HEMATOLOGY.2015
- **Delayed hematopoietic recovery after auto-SCT in patients receiving arsenic trioxide-based therapy for acute promyelocytic leukemia: a multi-center analysis** *BONE MARROW TRANSPLANTATION*
Mannis, G. N., Logan, A. C., Leavitt, A. D., Yanada, M., Hwang, J., Olin, R. L., Damon, L. E., Andreadis, C., Ai, W. Z., Gaensler, K. M., Greene, C. C., Gupta, N. K., Kaplan, et al
2015; 50 (1): 40-44

- **New Meets Old: A Case Study and Review of Novel Therapeutics for the Treatment of CLL in Older Patients** *JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK*
Gupta, N. K., Andreadis, C.
2014; 12 (10): 1371-1375
- **Diffuse Large B-cell Lymphoma** *Cancers in People with HIV and AIDS*
Gupta, N. K., Kaplan, L. D.
Springer.2014: 175–182
- **How I treat CNS lymphomas** *BLOOD*
Rubenstein, J. L., Gupta, N. K., Mannis, G. N., LaMarre, A. K., Treseler, P.
2013; 122 (14): 2318-2330
- **Outcome of patients with relapsed/refractory acquired immune deficiency syndrome-related lymphoma diagnosed 1999-2008 and treated with curative intent in the AIDS Malignancy Consortium** *LEUKEMIA & LYMPHOMA*
Bayraktar, U. D., Ramos, J. C., Petrich, A., Gupta, N., Lensing, S., Moore, P. C., Reid, E. G., Aboulafia, D. M., Ratner, L., Mitsuyasu, R., Cooley, T., Henry, D. H., Barr, et al
2012; 53 (12): 2383-2389
- **Fourth complete remission with immunosuppression withdrawal and irinotecan after both autologous and allogeneic transplants for diffuse large B cell lymphoma** *LEUKEMIA & LYMPHOMA*
Gupta, N. K., Barker, J. N., Young, J. W., Noy, A.
2009; 50 (12): 2075-2077
- **Differential effects of neurotoxic destruction of descending noradrenergic pathways on acute and persistent nociceptive processing** *PAIN*
Martin, W. J., Gupta, N. K., Loo, C. M., Rohde, D. S., Basbaum, A. I.
1999; 80 (1-2): 57-65